1. Цырлин В.А., Лопатина Е.В., Пеннияйнен В.А. Влияние β-адреноблокаторов на рост кардиомиоцитов в культуре ткани сердца. Артериальная гипертензия 2006;12(3):248−251.

2. Шляхто Е.В., Цырлин В.А., Сыренский А.В. и др. Противоишемическое действие ингибитора ангиотензин-превращающего фермента зофеноприла при острой ишемии миокарда в эксперименте. Артериальная гипертензия 2006;12(5):31−34.

3. Evangelista S, Manzini S.

4. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005;33(1):42−54.

5. Frascarelli S., Ghelardoni S., Ronca-Testoni S. et al. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 2004;43:294-299.

6. Gagnon C., Legault F., Geraldes P., Tanguay J.F., Lambert C. Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 2004;97(3):373−81.

7. Manolis A .,

8. Athanasopoulos G .,

9. Karatasakis G . et al. Pressor hormone profile during stress in hypertension: does vasopressin interfere with left ventricular hypertrophy? Clin Exp Hypertens 1993;15(3):539−55.

10. Motz W., Ringsgwandl G., Straner B.E. Regression of structural cardiovascular changes by antihypertensive therapy: effects on the heart in SHR. In: Hypertension ed. B. Folkow et al., Molndal, 1985:312−325.

11. de Nigris F .,

12. D'Armiento F.P .

13. Somma P . et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001;81(2-3):107−15.

14. Sargent C.A., Sleph P.G., Dzwonczyk S. et al. Cardioprotection in ischemic rat heart with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J Pharmacol Exp Ther 1992;265:609−618.

15. Swynghedauw B.

16. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79(1):215-62.

17. Yamashita C., Hayashi T., Mori T., Tazawa N., Kwak C.J., Nakano D, Sohmiya K., Okada Y., Kitaura Y, Matsumura Y. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007;30(12):1219−30.

18. Yamori Y., Tarazi R.C., Ooshima A. Effect of β-receptor-blocking agents on cardiovascular structural changes in spontaneously and noradrenaline-induced hypertension in rats. Clin Sci 1980;59:457−460.